RxDoctor Payments Data

Melissa Gross, MD

Addiction Psychiatry · Suffolk, VANPI 1942294582

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 97.2% of the total across 24 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 7 manufacturers reported payments, led by Teva Pharmaceuticals USA, Inc. at 40.4% of the total. Reporting peaked in 2019 at $378 and has fallen 94.3% since, to $21 in 2023.

$458in general payments, 2019–2025

Across 24 payments — averaging $19.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Teva Pharmaceuticals USA, Inc.$185
  • Alkermes, Inc.$115
  • Johnson & Johnson$53
  • Neurocrine Biosciences, Inc.$41
  • Sunovion Pharmaceuticals Inc.$32
  • Pfizer$21
  • plus $11 from 1 others

What the payments were for

  • Food & beverage$44597%
  • Education$133%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
23

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few addiction psychiatry providers in Virginiato place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$16,751
Medicare patients
26
Services billed
147

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
SavellaMilnacipran Hcl12$5,621
Vilazodone Hcl12$1,578
Quetiapine Fumarate ErQuetiapine Fumarate15$1,156
Mirtazapine32$440
Sertraline Hcl22$258
Lamotrigine18$210
Buspirone Hcl19$203
Trazodone Hcl12$115
Clonazepam33$105
Alprazolam24$47

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieSavella$11$5,62112 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few addiction psychiatry providers in Virginiaon file to place this against a meaningful peer group, so we don't.

Other addiction psychiatry in Suffolk

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →